JNCE News and Press, Jounce Therapeutics Inc. From 02/23/23

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Shutterstock We’re starting the day with a look at all the biggest pre-market stock movers traders need to know about on Thursday! Moving stocks this morning are earnings reports, merger plans, and more. ...

Jounce Therapeutics ( NASDAQ: JNCE ) is merging with U.K.-based Redx Pharma in an all stock deal after which the combined company will be known as Redx and listed on Nasdaq under the ticker REDX. The group will be focused on developing therapies for treating cancer and ...

Combined group will have a strong clinical pipeline and proven expertise in the discovery and development of highly selective therapeutics for the treatment of cancer and fibrotic disease RXC007, a next-generation selective ROCK2 inhibitor, to lead clinical pipeline; portfolio to includ...

Jounce Therapeutics ( NASDAQ: JNCE ) will let go of 57% of its employees as part of a restructuring. The stock is up 15% in after-hours trading. Jounce noted that because it needs additional funding for its clinical programs JTX-8064 and vopratelimab, both of which are in phas...

CAMBRIDGE, Mass., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (Nasdaq: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, announced today that it is reducing its workforce by approximately 57 percent....

Summary Jounce has recently announced that it has sold its entire rights to immunotherapy candidate GS-1181 to Gilead for $67 million. I expect the biotech company to now have around $170 million cash, with a market cap of about $55 million. In line with bearish biotech times, the s...

What Different Penny Stocks News Means Once you’ve familiarized yourself with the general landscape of penny stocks, it’s time to dive into the more specific news sources that can help you make money. One of the best ways to gain an advantage in penny stock investing is to s...

Jounce Therapeutics ( NASDAQ: JNCE ) is receiving $67M from Gilead Sciences ( NASDAQ: GILD ) in exchange for giving up rights to its phase 1 cancer immunotherapy GS-1811 (formerly JTX-1811). Jounce is up 59% in after-hours trading. Jounce ( JNCE ) and Gilead ( ...

-- Agreement Covers Buyout of Remaining Financial Obligations for Anti-CCR8 Antibody in Development as a Potential Treatment for Solid Tumors -- Gilead Sciences, Inc. (Nasdaq: GILD) and Jounce Therapeutics, Inc. (Nasdaq: JNCE) amended their existing license agreement for GS-1811 (former...

FOSTER CITY, Calif. and CAMBRIDGE, Mass., Dec. 27, 2022 (GLOBE NEWSWIRE) -- Gilead Sciences, Inc. (Nasdaq: GILD) and Jounce Therapeutics, Inc. (Nasdaq: JNCE) amended their existing license agreement for GS-1811 (formerly JTX-1811), enabling Gilead to buyout remaining contingent payments potential...